Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting Dated 28Th January, 2022

 We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Friday, 28th January 2022 at 3:00 pm had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the quarter ended December 31st, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; 2. Appointment of Ms. Jinkal Shah as a Company Secretary and Compliance Officer of the Company with effect from 28th January, 2022.
28-01-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for Board Meeting Of The Company On Friday, 28Th January, 2022

 Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Friday, 28th January 2022 at 3.00 pm at the Registered Office of the Company to transact inter - alia the following businesses: 1) To discuss, consider and approve Unaudited Financial Results of the Company for the Quarter ended December 31st, 2021. 2) Any other matter with the permission of the Chair Further in continuation of our intimation dated 31st December, 2021 and pursuant to Company's 'Code of Conduct for Prevention of Insider Trading' the Trading Window for dealing in the securities of the Company is closed from 1st January 2022 till 30th January 2022 (both days inclusive). The same has been circulated to the Directors, Key Managerial Personnel and Employees of the Company.
19-01-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Shareholding for the Period Ended December 31, 2021

 Fredun Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
11-01-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 In compliance to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018; we furnish hereunder the confirmation certificate received from the SEBI Registered Share Transfer Agent viz. Purva Sharegistry (India) Pvt. Ltd. for the quarter ended December 31st 2021.
10-01-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Statement Of Investor Complaints For The Quarter Ended December 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Fredun Nariman MedhoraDesignation :- Managing Director / Whole Time Director
07-01-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window

 Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, and 'Code of Conduct for Prevention of Insider Trading' of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), the trading window for dealing in securities of the Company will remain closed for designated persons and their immediate relatives with effect from 1* January, 2022 till 48 hours after the end of the Board Meeting wherein; the approval of Un-audited Financial Results for the Quarter ended 31 December 2021, would be considered, approved and declared. The said information is being notified to all designated persons under the above Regulations.
31-12-2021
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 This is in reference to the Analyst Meet via Zoom Platform that was scheduled on December 25, 2021 at 4:00 P.M. We would like to share with stakeholders that a great response was received from the Anlaysts/Investors towards this Meeting. Questions in regards to procurement, capacity building, marketing, short term / long term debts of the Company, expenditure on R&D, Stock Management, tax burden & GST, new upcoming projects, cash credit and cash management, working capital requirements, Human Resources / workforce planning, factoring, overall Industry growth prospects were some of the aspects on which Anlaysts/Investors had raised their queries. Mr. Fredun Medhora, Managing Director of the Company addressed all these queries; as raised by the various Investors to their satisfaction. The Conference call started as scheduled at 4:00 P.M. and concluded at 6.25 P.M. No unpublished price sensitive information (UPSI) was discussed during the interactions in the said Zoom Meeting.
25-12-2021
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 This is in reference to the Analyst Meet via Zoom Platform that was scheduled on December 25, 2021 at 4:00 P.M. We would like to share with stakeholders that a great response was received from the Anlaysts/Investors towards this Meeting. Questions in regards to procurement, capacity building, marketing, short term / long term debts of the Company, expenditure on R&D, Stock Management, tax burden & GST, new upcoming projects, cash credit and cash management, working capital requirements, Human Resources / workforce planning, factoring, overall Industry growth prospects were some of the aspects on which Anlaysts/Investors had raised their queries. Mr. Fredun Medhora, Managing Director of the Company addressed all these queries; as raised by the various Investors to their satisfaction. The Conference call started as scheduled at 4:00 P.M. and concluded at 6.25 P.M. No unpublished price sensitive information (UPSI) was discussed during the interactions in the said Zoom Meeting.
25-12-2021
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 This is to inform you that pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the following analyst had physical meeting with Senior Management of the Company at our factory located at Palghar.
24-12-2021
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Intimation of Schedule of meeting with various group of investors/ analysts.
24-12-2021
Next Page
Close

Let's Open Free Demat Account